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Introduction {#sec001}
============

Extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae* and carbapenem-resistant *Enterobacteriaceae* (CRE) pose a serious public health threat due to their extensive antibiotic resistance. Many ESBL and CRE infections are healthcare-associated infections (HAIs), meaning they occur in long-term healthcare facilities and hospitals. *Klebsiella pneumoniae* (Kp) is an environmentally ubiquitous member of the *Enterobacteriaceae* family that can acquire antibiotic resistance genes \[[@ppat.1008010.ref001]\], and thus is a leading cause of ESBL-producing *Enterobacteriaceae* infections \[[@ppat.1008010.ref002]\] and HAIs \[[@ppat.1008010.ref003]\]. Mortality rates in patients infected with antibiotic resistant Kp often exceed 40% \[[@ppat.1008010.ref004]\]. Disturbingly, reports of hypervirulent clones of Kp acquiring mobile antibiotic resistance genes are becoming more frequent \[[@ppat.1008010.ref005],[@ppat.1008010.ref006]\], posing a significant global threat to human health. As the efficacy of antibiotics diminishes and therapeutic options for patients infected with antibiotic resistant strains of Kp become increasingly limited, a better understanding of how Kp establish productive infections is necessary for the development of novel diagnostics and interventions to combat these dangerous bacteria.

To establish a productive infection, bacterial pathogens such as Kp must acquire nutrients from the host environment. Subsequently, metabolic flexibility dictates the capacity of pathogens to invade different niches \[[@ppat.1008010.ref007]--[@ppat.1008010.ref010]\]. This flexibility is defined by the ability of a bacterial pathogen to acquire and utilize different metabolites. For example, *Salmonella enterica* serotype Typhimurium uses tetrathionate as an electron acceptor, providing a fitness advantage in the gut, whereas this advantage is not conferred in the spleen due to the lack of tetrathionate \[[@ppat.1008010.ref011]\]. Interestingly, Kp potentially exhibits diversity in metabolism and nutrient acquisition, as indicated by the ability to cause a wide range of severe infections, including pneumonia, bacteremia, urinary tract infection, and pyogenic liver abscess \[[@ppat.1008010.ref012]\]. Additionally, infectious Kp frequently originates from sites of colonization \[[@ppat.1008010.ref013]--[@ppat.1008010.ref015]\], including the gut and nasopharynx \[[@ppat.1008010.ref016],[@ppat.1008010.ref017]\]; however, the impact of metabolic flexibility on Kp pathogenesis has not received significant attention.

Metabolites necessary for niche invasion by pathogens can be acquired directly from the host, through the metabolic activity of other microorganisms, or by *de novo* synthesis. Limitation of access to these nutrients by the host is a universal means of impeding niche invasion by bacterial pathogens \[[@ppat.1008010.ref018]--[@ppat.1008010.ref021]\]. For example, iron is critical for niche invasion and subsequent pathogenesis, and thus the host actively sequesters iron from invading bacteria \[[@ppat.1008010.ref018]\]. To overcome this nutrient limitation, pathogens such as Kp encode a variety of proteins and small molecules to harvest sequestered iron, including the family of low molecular weight chelators known as siderophores \[[@ppat.1008010.ref022]\]. Consequently, the host further prevents iron acquisition by sequestering bacterial siderophores with the innate immune molecule Lipocalin 2 (Lcn2) \[[@ppat.1008010.ref023]\]. In turn, Kp circumvents Lcn2 activity by expressing alternative siderophores \[[@ppat.1008010.ref024]\]. Interestingly, Lcn2 has immunomodulatory effects \[[@ppat.1008010.ref025]\], suggesting that the impact of Lcn2 during Kp infection is not limited to sequestration of iron and that there are likely other Lcn2-dependent Kp factors; however, this has yet to be experimentally addressed.

To discover Kp genes that are conditionally essential in the presence of Lcn2, we undertook an InSeq experiment comparing lung infection in *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ murine backgrounds. This revealed multiple conditionally essential genes, including the citrate (Si)-synthase gene *gltA*. *In vitro* studies indicated that the interaction between GltA and Lcn2 is indirect. Further analysis revealed that deletion of *gltA* dramatically reduces metabolic flexibility, leading to glutamate family amino acid auxotrophy and a severe limitation of glycolytic substrate utilization. This limitation of metabolic flexibility is partially complemented during lung infection by deletion of *Lcn2*, corresponding to an increase in glutamate family amino acid concentrations in the lung. Addition of these amino acids to growth media and bronchoalveolar fluid is sufficient to restore the loss of GltA. Using multiple murine models of infection, we show that GltA is not necessary for blood infection, but is necessary in the spleen, liver, and gut. Together, these data reveal how Kp metabolic flexibility, conferred by the citrate (Si)-synthase GltA, impacts site-specific fitness during infection.

Results {#sec002}
=======

To comprehensively identify novel Lcn2-dependent Kp factors during lung infection, we employed a previously described transposon library in the Kp strain KPPR1 \[[@ppat.1008010.ref026],[@ppat.1008010.ref027]\]. To this end, *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice \[[@ppat.1008010.ref028]\] were retropharyngeally inoculated with a pool of \~25,000 transposon mutants ([S1 Fig](#ppat.1008010.s001){ref-type="supplementary-material"}). Twenty-four hours after inoculation total lung CFU were collected for DNA extraction and InSeq analysis, as previously described \[[@ppat.1008010.ref026]\]. After filtering, each sample had greater than 50 million reads corresponding to greater than 20,000 unique transposon insertions inside of open reading frames ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}). To identify Lcn2-dependent Kp factors, the ratio of transposon insertion reads within each gene between the *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ lung output pools (mean reads per gene were 169 and 156, respectively) was calculated to generate a fitness index. Over 1,600 genes were significantly enriched in either mouse background indicating a potential interaction with Lcn2, including *entB*, which is required to synthesize both enterobactin and the Lcn2-evading siderophore salmochelin ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}). To limit our analysis, only genes with a significant fitness index greater or less than 3 standard deviations from the mean were considered Lcn2-dependent, leading to a final list of 43 candidate genes ([Table 1](#ppat.1008010.t001){ref-type="table"}, [S1 Fig](#ppat.1008010.s001){ref-type="supplementary-material"}, [S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}).

10.1371/journal.ppat.1008010.t001

###### Lcn2-dependent *K*. *pneumoniae* factors.

![](ppat.1008010.t001){#ppat.1008010.t001g}

  Locus ID (VK055\_\#)   Gene Name   Log~10~ Ratio (*Lcn2*^*+/+*^: *Lcn2*^*-/-*^)   *P* Value   GenBank Definition
  ---------------------- ----------- ---------------------------------------------- ----------- ----------------------------------------------------------------
  2967                   *phnG*      -2.27                                          5.82E-11    phosphonate C-P lyase system protein PhnG
  2193                   * *         -2.24                                          2.84E-14    glyoxalase
  1802                   *gltA*      -2.23                                          0.00E+00    citrate (Si)-synthase
  358                    * *         -2.14                                          4.44E-16    putative siderophore transport system ATP-binding protein YusV
  852                    * *         -2.08                                          1.39E-17    diguanylate cyclase domain protein
  4742                   * *         -1.97                                          7.94E-21    hypothetical protein
  1264                   * *         -1.91                                          3.56E-266   putative enzyme related to aldose 1-epimerase
  679                    *pqqB*      -1.89                                          1.46E-11    coenzyme PQQ biosynthesis protein B
  4503                   * *         -1.88                                          7.45E-09    hypothetical protein
  3425                   * *         -1.80                                          9.31E-10    putative efflux pump outer membrane protein TtgC
  2801                   * *         -1.76                                          0.00E+00    bacterial regulatory, GntR family protein
  406                    *budC*      -1.76                                          0.00E+00    diacetyl reductase (S-acetoin forming)
  1665                   *nikE*      -1.74                                          2.98E-08    nickel import ATP-binding protein NikE2
  494                    * *         -1.73                                          9.41E-30    efflux transporter, RND family, MFP subunit
  4907                   * *         -1.72                                          4.07E-09    yejG-like family protein
  4402                   *cysD*      -1.71                                          0.00E+00    CysD
  4417                   * *         -1.71                                          9.54E-07    MarR family protein
  23                     *rcsA*      -1.68                                          3.82E-11    transcriptional regulator of capsular polysaccharide synthesis
  3697                   *envZ*      -1.66                                          0.00E+00    EnvZ
  1081                   * *         -1.64                                          7.63E-06    bacterial regulatory helix-turn-helix, LysR family protein
  2100                   * *         -1.64                                          4.62E-14    primosomal replication PriB and PriC family protein
  5166                   * *         -1.56                                          5.12E-12    hypothetical protein
  5008                   *udk*       -1.55                                          0.00E+00    deoxycytidine triphosphate deaminase
  1530                   * *         -1.55                                          2.84E-10    hypothetical protein
  2620                   * *         -1.54                                          1.08E-09    hypothetical protein
  4957                   * *         -1.54                                          1.14E-80    osmoprotectant transport system ATP-binding protein
  2890                   * *         -1.49                                          4.44E-37    hypothetical protein
  2734                   * *         1.68                                           3.46E-103   hypothetical protein
  3005                   *soxR*      1.69                                           1.54E-08    redox-sensitive transcriptional activator SoxR
  631                    * *         1.70                                           4.95E-23    zinc-binding dehydrogenase family protein
  503                    * *         1.74                                           3.82E-11    pyridoxal kinase
  1089                   * *         1.79                                           4.02E-21    type VI secretion lipofamily protein
  2579                   * *         1.80                                           9.59E-27    CreA family protein
  1763                   *galE*      1.90                                           2.91E-11    UDP-glucose 4-epimerase
  3375                   * *         1.91                                           1.20E-19    hypothetical protein
  3418                   * *         1.92                                           1.94E-55    PrpF family protein
  3618                   *nikC*      1.93                                           7.05E-18    nickel ABC transporter, permease subunit NikC
  4369                   * *         1.97                                           0.00E+00    binding-protein-dependent inner membrane transport system
  2230                   *iraP*      2.02                                           8.70E-46    anti-adaptor protein for sigmaS stabilization
  2009                   * *         2.04                                           1.57E-20    hypothetical protein
  4943                   * *         2.07                                           1.46E-11    OprB family protein
  953                    * *         2.33                                           5.55E-17    response regulator
  1873                   *ybeC*      2.45                                           3.55E-15    TatE

Sixteen transposon mutants displayed enhanced fitness when Lcn2 is present, and 27 displayed enhanced fitness when Lcn2 is absent ([Table 1](#ppat.1008010.t001){ref-type="table"}). Interestingly, the most common molecular function of genes enriched in both backgrounds was metabolism \[[@ppat.1008010.ref029]\], accounting for 10 of 43 genes (23.3%, [S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}). This was followed by membrane transport (6 of 43, 14.0%), including the putative siderophore transport system ATP-binding protein YusV, transcription factors (3 of 43, 7.0%), two-component systems (3 of 43, 6.9%), DNA repair and recombination (2 of 43, 4.7%), protein export (1 of 43, 2.3%), and quorum sensing (1 of 43, 2.3%). The molecular function of 17 (39.5%) of these genes has not been characterized. Three genes (VK055_1802, VK055_3697, and VK055_4417) enriched in the *Lcn2*^*-/-*^ background were previously identified as fitness factors during Kp lung infection \[[@ppat.1008010.ref026]\] ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}, in italics). Five genes displayed a greater than 100-fold enrichment in the *Lcn2*^*-/-*^ lung pool, and one, VK055_1802, had a *P* value less than 10^−300^ ([Table 1](#ppat.1008010.t001){ref-type="table"}, [S1 Fig](#ppat.1008010.s001){ref-type="supplementary-material"}, [S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}). VK055_1802 is annotated as *gltA*, which encodes the citric acid cycle enzyme citrate (Si)-synthase \[[@ppat.1008010.ref030]\]. Together, these data indicate that metabolism is critical for the interaction between KPPR1 and Lcn2 during lung infection and that *gltA* is potentially a Lcn2-dependent metabolic Kp gene. To confirm the role of *gltA* during lung infection and its dependence on Lcn2, we constructed an isogenic *gltA* mutant \[[@ppat.1008010.ref031]\] and complemented the gene *in trans*. The KPPR1Δ*gltA* strain displayed no growth defect compared to WT KPPR1 in nutrient-rich media ([S1 Fig](#ppat.1008010.s001){ref-type="supplementary-material"}). This mutant was mixed 1:1 with its WT parent strain, then inoculated retropharyngeally in both *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice. As observed with InSeq data, the KPPR1Δ*gltA* mutant displayed a 67-fold mean fitness defect compared to the WT KPPR1 strain in the *Lcn2*^*+/+*^ lung that was partially alleviated in the *Lcn2*^*-/-*^ lung ([Fig 1A](#ppat.1008010.g001){ref-type="fig"}, [S2 Fig](#ppat.1008010.s002){ref-type="supplementary-material"}). Mono-infections in *Lcn2*^*+/+*^ mice also revealed a significant defect in growth of the KPPR1Δ*gltA* mutant ([S2 Fig](#ppat.1008010.s002){ref-type="supplementary-material"}). Given that citrate can act as a weak siderophore \[[@ppat.1008010.ref032]\] and is a building block of complex siderophores \[[@ppat.1008010.ref033],[@ppat.1008010.ref034]\], we hypothesized that loss of siderophore activity through deletion of *gltA* may explain the observed loss of fitness. To test this hypothesis, we grew a variety of KPPR1-derived strains in RPMI plus 10% human serum, which is iron limited to Kp due to the activity of transferrin \[[@ppat.1008010.ref035]\], with or without recombinant human Lcn2. The WT KPPR1 strain was not affected by the presence of Lcn2; however, the siderophore-null KPPR1Δ*entB*Δ*ybtS* strain \[[@ppat.1008010.ref036]\] was unable to grow in Lcn2-free conditions, consistent with the importance of siderophore function for KPPR1 growth. The enterobactin-dependent KPPR1Δ*iroA*Δ*ybtS* strain \[[@ppat.1008010.ref035]\] was able to grow in Lcn2-free conditions, but unable to grow in the presence of Lcn2, validating the antagonistic relationship between enterobactin and Lcn2 ([Fig 1B](#ppat.1008010.g001){ref-type="fig"}). Deletion of *gltA* had no impact on growth in the presence of Lcn2 ([Fig 1B](#ppat.1008010.g001){ref-type="fig"}), indicating that citrate produced by GltA is not involved in detectable siderophore activity and suggesting that the relationship between *gltA* and Lcn2 during lung infection is indirect.

![The Kp citrate synthase, *gltA*, interacts indirectly with Lcn2 during lung infection.\
(A) A *gltA* (VK055_1802) mutant was constructed and used to validate InSeq findings. C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were retropharyngeally inoculated with approximately 1×10^6^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA*. Lung bacterial burden was measured after 24 hours, and log~10~ competitive index of the mutant strain compared to the WT strain was calculated for each mouse strain (n = 10, mean displayed, \**P* \< 0.05, \*\*\**P* \< 0.0005, \*\*\*\**P* \< 0.00005, one-sample *t* test or Student's *t* test). (B) WT KPPR1 and various isogenic mutants were grown in RPMI + 10% (v/v) heat-inactivated resting human serum ± purified recombinant human Lcn2 overnight, then total CFU was enumerated by dilution plating on selective media (n = 3--4, mean displayed ± SEM, \*\*\*\**P* \< 0.00005, Student's *t* test).](ppat.1008010.g001){#ppat.1008010.g001}

Given that citrate (Si)-synthase performs an irreversible oxidation step in the citric acid cycle, we next postulated that the relationship between *gltA* and Lcn2 is due to disruption of the TCA cycle. In addition to oxidative metabolism, the TCA cycle provides a number of key carbon skeletons for the biosynthesis of amino acids. Growth of the KPPR1Δ*gltA* mutant was partially restored when citrate was provided as the sole carbon source as measured by area under curve (AUC) analysis \[[@ppat.1008010.ref037],[@ppat.1008010.ref038]\] ([S3 Fig](#ppat.1008010.s003){ref-type="supplementary-material"}) although both the WT and mutant grow slowly. Mutant growth was not restored when citrate is provided in combination with glucose ([S3 Fig](#ppat.1008010.s003){ref-type="supplementary-material"}), as citrate is able to inhibit glycolysis through allosteric inhibition of phosphofructokinase \[[@ppat.1008010.ref039]\].To determine if loss of GltA affects Kp metabolic capabilities, we performed an unbiased screen of carbon and nitrogen sources using the BioLog system to identify conditions differentially permissive to KPPR1Δ*gltA* growth \[[@ppat.1008010.ref040]\]. Both strains were cultured under 282 different conditions, and growth was measured after 24 hours ([Fig 2A](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}). These experiments revealed 129 conditions in which WT KPPR1 significantly outgrew KPPR1Δ*gltA* and three conditions (L-arginine, L-glutamine, and ethylenediamine) in which KPPR1Δ*gltA* significantly outgrew WT KPPR1 ([Fig 2A](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}). Complete BioLog analysis revealed that deletion of *gltA* resulted in glutamate family amino acid (glutamate, glutamine, proline, histidine, and arginine) auxotrophy, as indicated by the ability of these amino acids to support growth of the KPPR1Δ*gltA* strain ([Fig 2B](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}). The glutamate family of amino acids is critical for multiple overlapping cellular functions, as these amino acids act as the juncture between glycolysis and gluconeogenesis \[[@ppat.1008010.ref041]\], play an intermediary role in nitrogen assimilation \[[@ppat.1008010.ref042]\], and act as a building block for peptidoglycan \[[@ppat.1008010.ref043]\] and proteins ([S4 Fig](#ppat.1008010.s004){ref-type="supplementary-material"}). Consistent with the finding that glutamate family amino acids complement the loss of GltA, some dipeptides containing these residues were partially or fully able to support growth of the KPPR1Δ*gltA* strain, whereas dipeptides without these residues did not ([Fig 2C](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}). To confirm our findings, WT KPPR1, KPPR1Δ*gltA*, and pGltA complemented strains were grown in minimal medium containing glucose. When glucose is the sole carbon source, the KPPR1Δ*gltA* strain is unable to grow ([Fig 3A and 3B](#ppat.1008010.g003){ref-type="fig"}), and this phenotype was replicated for a variety of conditions wherein only a single sugar was provided as a sole carbon source ([S5 Fig](#ppat.1008010.s005){ref-type="supplementary-material"}). The pGltA plasmid or addition of 10 mM glutamate fully restored growth of the KPPR1Δ*gltA* strain ([Fig 3A and 3B](#ppat.1008010.g003){ref-type="fig"}) and growth was also fully or partially complemented by addition of 10 mM glutamine, proline, and α-ketoglutarate ([Fig 3C--3F](#ppat.1008010.g003){ref-type="fig"}). Additionally, the restoration of KPPR1Δ*gltA* growth in M9 medium containing glucose by addition of glutamate is dose-dependent ([S6 Fig](#ppat.1008010.s006){ref-type="supplementary-material"}). Together, these data indicate that deletion of *gltA* results in glutamate family amino acid auxotrophy.

![Deletion of *gltA* leads to diminished metabolic flexibility and distinct amino acid auxotrophy.\
(A) Heatmap summarizing BioLog Phenotype Microarray analysis of WT KPPR1 and KPPR1Δ*gltA* growth in 282 carbon and nitrogen limited growth conditions indicates multiple conditions that sustained growth of WT KPPR1, but not KPPR1Δ*gltA*. (B) A subset of growth conditions summarizing glycolysis and non-essential amino acid biosynthesis that indicates a distinct amino acid auxotrophy is induced by deletion of *gltA*. Arrows from citric acid cycle intermediates indicate amino acids that utilize these intermediates for biosynthesis. (C) A subset of growth conditions summarizing dipeptide utilization that further indicates induction of a distinct amino acid auxotrophy by deletion of *gltA* (n = 3, mean displayed, \**P* \< 0.05, Student's *t* test). Underlined substrates support equivalent or enhanced growth of KPPR1Δ*gltA* relative to WT KPPR1.](ppat.1008010.g002){#ppat.1008010.g002}

![Auxotrophy due to deletion of *gltA* is functionally complemented by glutamate and glutamate family amino acids.\
(A) WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA were grown in M9 minimal media + 0.4% glucose with or without 10 mM glutamate (n = 3, mean displayed ± SEM). (B) AUC analysis of WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA growth in M9 minimal media +0.4% glucose with 10 mM glutamate (n = 3, \*\*\*\**P* \< 0.00005 compared to all other groups, Tukey's multiple comparison test following ANOVA, mean displayed ± SEM). WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 0.4% glucose with 10 mM (C) glutamine, (D) proline, and (E) 2-α-ketoglutarate (n = 3, mean displayed ± SEM). "+AA" label indicates addition of amino acids to growth media at concentrations indicated in graph title. (F) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* growth in M9 minimal media + 0.4% glucose + specific amino acid (n = 3, \*\*\**P* \< 0.0005, \*\*\*\**P* \< 0.00005, Tukey's multiple comparison test following ANOVA, mean displayed ± SEM). Data presented in panels C-E were generated simultaneously, but graphed separately for ease of visualization.](ppat.1008010.g003){#ppat.1008010.g003}

Airway lining fluid can be a nutritional source for bacteria living in the respiratory tract, with measurable levels of amino acids in both human and mouse bronchioloalveolar lavage fluid (BALF) \[[@ppat.1008010.ref044]--[@ppat.1008010.ref047]\]. To determine if the differences in KPPR1Δ*gltA* fitness in *Lcn2*^+/+^ and *Lcn2*^-/-^ lungs is attributable to differences in amino acid concentrations, whole BALF was collected from uninfected mice and used as a bacterial growth medium. BALF from both mouse strains sustained growth of WT KPPR1; however, KPPR1Δ*gltA* growth was defective in *Lcn2*^+/+^ BALF but not in *Lcn2*^-/-^ BALF ([Fig 4A and 4B](#ppat.1008010.g004){ref-type="fig"}). To determine if there are inherent differences in amino acid levels in the lungs of *Lcn2*^+/+^ and *Lcn2*^-/-^ mice that explain these differences in growth, we used gas chromatography--mass spectrometry to measure free amino acid content in BALF from uninfected mice. *Lcn2*^-/-^ BALF contains significantly higher levels of multiple amino acids, including those in the glutamate family of amino acids, and higher total protein content ([Table 2](#ppat.1008010.t002){ref-type="table"}, [S3 Data](#ppat.1008010.s012){ref-type="supplementary-material"}). Indeed, BALF from *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ are distinguishable based on their amino acid composition ([Fig 4C](#ppat.1008010.g004){ref-type="fig"}). This increase in amino acid and protein content likely explains the difference between KPPR1Δ*gltA* fitness in the *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ backgrounds by functionally complementing the loss of *gltA*. To test this premise, KPPR1Δ*gltA* was mixed 1:1 with its WT parent strain, then inoculated in BALF from *Lcn2*^*+/+*^ mice. Addition of glutamate and proline to *Lcn2*^*+/+*^ BALF was sufficient to restore the fitness of the KPPR1Δ*gltA* strain, as was *in trans* complementation of GltA ([Fig 4D](#ppat.1008010.g004){ref-type="fig"}). To assess if this effect was specific to glutamate family amino acids, we tested the ability of valine to restore the fitness of the KPPR1Δ*gltA* strain. Although its concentration was significantly higher in *Lcn2*^*-/-*^ BALF compared to *Lcn2*^*+/+*^ BALF ([Table 2](#ppat.1008010.t002){ref-type="table"}, [Fig 4C](#ppat.1008010.g004){ref-type="fig"}, [S3 Data](#ppat.1008010.s012){ref-type="supplementary-material"}), addition of valine was unable to restore the fitness of the KPPR1Δ*gltA* strain ([Fig 4D](#ppat.1008010.g004){ref-type="fig"}). Together, these data indicate that the loss of fitness observed in the *Lcn2*^*+/+*^ lung is due to a reduction in metabolic flexibility induced by *gltA* deletion, and the increased concentration of glutamate family amino acids in the *Lcn2*^*-/-*^ background rescues the loss of *gltA*.

![Bronchoalveolar lavage fluid from *Lcn2*^*-/-*^ mice can sustain growth of KPPR1Δ*gltA* due to increased amino acid levels.\
(A) Murine bronchoalveolar lavage fluid (BALF) was obtained from uninfected C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice, and WT KPPR1 and KPPR1Δ*gltA* were grown in BALF (representative curve displayed). (B) Area under curve (AUC) analysis was used to compare growth of WT KPPR1 and KPPR1Δ*gltA* in *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ BALF. (n = 7--11 per group, paired *t* test, mean displayed ± SEM, \*\**P* \< 0.005). (C) Heatmap of amino acid concentrations in BALF obtained from uninfected C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice subjected to metabolomic analysis (n = 6--7 mice per group). Blue histogram in inset indicates composite amino acid concentration values in heatmap matrix. (D) Murine bronchoalveolar lavage fluid obtained from uninfected C57BL/6J mice with or without amino acids was inoculated with a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA* or WT KPPR1 and KPPR1Δ*gltA*pGltA. Bacterial burden was measured after 24 hours, and log~10~ competitive index of the mutant strain compared to the WT strain was calculated for each sample (n = 4 per group, \*\**P* \< 0.005, \*\*\**P* \< 0.0005, \*\*\*\**P* \< 0.00005, one-sample *t* test or Tukey's multiple comparison test following ANOVA).](ppat.1008010.g004){#ppat.1008010.g004}

10.1371/journal.ppat.1008010.t002

###### Summary of amino acid and protein quantification from *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ BALF.

![](ppat.1008010.t002){#ppat.1008010.t002g}

  Metabolite[\*](#t002fn001){ref-type="table-fn"}   *Lcn2*^*+/+*^ BALF (mean ± S.D.)   *Lcn2*^*-/-*^ BALF (mean ± S.D.)   Fold change   *P* Value    Adjusted *P* Value
  ------------------------------------------------- ---------------------------------- ---------------------------------- ------------- ------------ --------------------
  Total protein                                     275 ± 100                          457 ± 146                          1.66          0.0513       \-
  Total free amino acids                            276 ± 66.2                         405 ± 93.6                         1.47          **0.0221**   \-
  Alanine                                           31.4 ± 10.6                        48.6 ± 11.9                        1.55          **0.0350**   **0.0186**
  Alpha-aminoisobutyric acid                        0.22 ± 0.05                        0.46 ± 0.06                        2.03          **0.0012**   **0.0019**
  Asparagine                                        6.54 ± 1.07                        8.47 ± 2.09                        1.29          0.0734       **0.0346**
  Aspartic acid                                     11.7 ± 6.73                        12.6 ± 4.53                        1.08          0.2949       0.1123
  Cystine                                           1.03 ± 0.45                        0.34 ± 0.28                        0.34          **0.0082**   **0.0054**
  Glutamate                                         9.85 ± 3.86                        16.7 ± 9.87                        1.70          **0.0350**   **0.0186**
  Glutamine                                         74.1 ± 25.2                        95.3 ± 24.2                        1.29          0.1807       0.0723
  Glycine                                           43.4 ± 8.55                        55.9 ± 12.9                        1.29          0.0513       **0.0256**
  Histidine                                         8.59 ± 2.37                        10.3 ± 1.84                        1.21          0.1375       0.0579
  Isoleucine                                        5.89 ± 1.69                        10.1 ± 1.98                        1.73          **0.0047**   **0.0037**
  Leucine                                           11.2 ± 3.01                        19.7 ± 4.10                        1.76          **0.0023**   **0.0023**
  Lysine                                            19.3 ± 4.92                        25.4 ± 8.81                        1.31          0.1375       0.0579
  Methionine                                        3.99 ± 1.19                        9.64 ± 1.42                        2.41          **0.0012**   **0.0019**
  Ornithine                                         3.27 ± 1.18                        6.77 ± 1.73                        2.07          **0.0047**   **0.0037**
  Phenylalanine                                     7.95 ± 1.19                        13.0 ± 3.04                        1.64          **0.0023**   **0.0023**
  Proline                                           5.95 ± 1.37                        11.8 ± 2.42                        2.00          **0.0012**   **0.0019**
  Sarcosine                                         0.23 ± 0.04                        0.35 ± 0.08                        1.51          **0.0140**   **0.0086**
  Threonine                                         9.35 ± 2.07                        17.6 ± 4.02                        1.89          **0.0012**   **0.0019**
  Tyrosine                                          4.78 ± 0.83                        9.87 ± 2.01                        2.06          **0.0012**   **0.0019**
  Tryptophan                                        3.73 ± 1.48                        6.92 ± 1.91                        1.85          **0.0082**   **0.0054**
  Valine                                            13.6 ± 4.20                        25.4 ± 3.96                        1.86          **0.0023**   **0.0023**

\*Total protein concentration in μg/mL, all amino acid concentrations in μM

We next hypothesized that the loss of *gltA* would not affect bacterial growth in a physiologically relevant amino acid rich environment, such as sera \[[@ppat.1008010.ref048]\]. In minimal medium containing 20% heat-inactivated serum, no differences in growth were observed in heat-inactivated serum between WT KPPR1 and KPPR1Δ*gltA* strains ([Fig 5A and 5B](#ppat.1008010.g005){ref-type="fig"}), and these results were replicated in non-heat-inactivated serum ([S7 Fig](#ppat.1008010.s007){ref-type="supplementary-material"}). To determine if amino acid levels in reported in human blood are sufficient to functionally complement the loss of *gltA*, we tested the growth of WT KPPR1 and KPPR1Δ*gltA* strains in minimal medium with serum-level concentrations of glutamine, glutamate, and proline \[[@ppat.1008010.ref049],[@ppat.1008010.ref050]\], which are higher than those measured in BALF ([Table 2](#ppat.1008010.t002){ref-type="table"}). Indeed, serum-level concentrations of glutamine, glutamate, and proline were able to restore growth of the KPPR1Δ*gltA* strain ([Fig 5C and 5D](#ppat.1008010.g005){ref-type="fig"}). These data support the indication that glutamate family amino acid auxotrophy induced by deletion of *gltA* is the basis of the loss of fitness in amino acid deplete environments, such as the *Lcn2*^*+/+*^ lung.

![*gltA* is dispensable for growth in mouse serum.\
(A) WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 20% heat-inactivated murine serum without glucose. (B) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* growth in M9 minimal media + 20% heat-inactivated murine serum without glucose (n = 3, Student's t-test, mean displayed ± SEM). (C) WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA were grown M9 minimal media + 0.4% glucose with physiological levels of amino acids present in human serum (n = 3, mean displayed ± SEM). (D) AUC analysis of WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA growth M9 minimal media + 0.4% glucose with physiological levels of amino acids present in human serum (n = 3, \*\*\*\**P* \< 0.00005 compared to all other groups, Tukey's multiple comparison test following ANOVA, mean displayed ± SEM). "+AA" label indicates addition of amino acids to growth media at concentrations indicated in graph title.](ppat.1008010.g005){#ppat.1008010.g005}

The differential necessity of *gltA* for growth in BALF and serum led us to hypothesize that *gltA* may be a fitness factor only in certain body sites where Kp infections occur. To test this hypothesis, we first employed a peritoneal injection murine model of Kp infection. Consistent with results from an aspiration route, KPPR1Δ*gltA* was at a competitive disadvantage compared to WT KPPR1 when reaching the *Lcn2*^*+/+*^ lung through a hematogenous route, and this disadvantage was alleviated in the *Lcn2*^*-/-*^ lung ([Fig 6A](#ppat.1008010.g006){ref-type="fig"}, [S8 Fig](#ppat.1008010.s008){ref-type="supplementary-material"}). Consistent with *ex vivo* serum growth, KPPR1Δ*gltA* was not competitively disadvantaged in the blood of either mouse background but was less fit in the spleen and liver of *Lcn2*^*+/+*^ mice ([Fig 6A](#ppat.1008010.g006){ref-type="fig"}, [S8 Fig](#ppat.1008010.s008){ref-type="supplementary-material"}).

![*gltA* influences site-specific fitness during bacteremia and oral infection.\
(A) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were intraperitoneally inoculated with approximately 5×10^5^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA*. Bacterial burden in the blood, spleen, liver, and lung was measured after 24 hours, and log~10~ competitive index of the mutant strain compared to the WT strain was calculated for each mouse strain (n = 9--11 per group, mean displayed, \**P* \< 0.05, \*\*\*\**P* \< 0.00005, one-sample *t* test or Student's *t* test). (B) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were orally inoculated with approximately 5×10^6^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA*. After 48 hours, mice were euthanized, cecum bacterial load was measured, and log~10~ competitive index of the mutant strain compared to the WT strain was calculated for each mouse strain (n = 8--9 per group, mean displayed, \**P* \< 0.05, Student's *t* test).](ppat.1008010.g006){#ppat.1008010.g006}

Next, we assessed the role of *gltA* in the large intestine. Results from our metabolic screen ([Fig 2A](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}) indicate that the KPPR1Δ*gltA* strain is unable to utilize glycolytic substrates without the presence of amino acids that rescue the loss of GltA. Glycolytic metabolism has been shown to be critical for *Escherichia coli* gut colonization \[[@ppat.1008010.ref051]--[@ppat.1008010.ref053]\], thus we hypothesized that the KPPR1Δ*gltA* strain may be less fit in the gut. Indeed, the KPPR1Δ*gltA* strain was unable to grow with multiple single sugars, representative of the sugars available during gut colonization as a carbon source ([S5 Fig](#ppat.1008010.s005){ref-type="supplementary-material"}) \[[@ppat.1008010.ref051]--[@ppat.1008010.ref053]\]. To test the role of *gltA* in intestinal colonization, we gavaged *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice with approximately 5×10^6^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA*. We found that GltA is a fitness factor for cecal colonization in both the *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ background ([Fig 6B](#ppat.1008010.g006){ref-type="fig"}, [S8 Fig](#ppat.1008010.s008){ref-type="supplementary-material"}) and the mutant has a defect in mono-inoculation that approached statistical significance (P = 0.06; [S8 Fig](#ppat.1008010.s008){ref-type="supplementary-material"}).

Finally, we aimed to assess the ability of glutamate family amino acids to alleviate *gltA* deletion-induced auxotrophy in organ homogenates where fitness defects were observed. As was observed with BALF ([Fig 4D](#ppat.1008010.g004){ref-type="fig"}), the addition of glutamate was sufficient to restore the fitness of the KPPR1Δ*gltA* strain in both spleen and liver organ homogenates from *Lcn2*^*+/+*^ mice ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}). Proline was sufficient to restore the fitness of the KPPR1Δ*gltA* strain in spleen homogenate ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}), though not in liver homogenate ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}). Addition of valine had no impact on the fitness of the KPPR1Δ*gltA* strain; however, complementation of GltA *in trans* was able to partially but significantly alleviate deletion of *gltA* ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}). Similarly, in cecal homogenates, addition of glutamate completely restored and proline partially restored the fitness of the KPPR1Δ*gltA* strain ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}), and addition of valine had no impact ([S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}). Together, these data show that *gltA* influences site-specific fitness during infection in various body sites through conferring metabolic flexibility, and that *gltA* deletion-induced auxotrophy can be alleviated by the glutamate family of amino acids in these body sites.

Discussion {#sec003}
==========

The ability of a bacterial cell to utilize available nutrients upon encountering a new environment, referred to as metabolic flexibility, is critical for its survival and success. Bacteria must control highly interconnected metabolic pathways that are quickly activated based on substrate availability in their local environment. Central carbon metabolism connects many pathways in the cell by providing carbon skeletons for biosynthesis of macromolecular building blocks and conversely represents convergence points for the catabolism of macromolecules. Central carbon metabolism is comprised of glycolysis, gluconeogenesis, the Entner-Doudoroff pathway, the pentose phosphate pathway, and the citric acid cycle. The research presented here identifies the citric acid cycle component, citrate (Si)-synthase (GltA), as a critical mediator of metabolic flexibility in Kp, and this metabolic flexibility drastically influences fitness during infection in a site-specific manner. Using multiple murine models of infection in *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ backgrounds, we show that GltA is a fitness factor during lung infection by direct and hematogenous routes but is not necessary for bacteremia. Additionally, GltA is necessary for gut colonization, which frequently precedes infection \[[@ppat.1008010.ref012],[@ppat.1008010.ref013]\]. The necessity of GltA is likely determined by the nutrient composition of each respective body site, specifically access to amino acids that the bacteria cannot otherwise synthesize *de novo*. This is supported by the observation of differential fitness of KPPR1Δ*gltA* in the *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ lung, which have different endogenous levels of amino acids. Together, these data provide new insight into how Kp metabolic flexibility determines fitness during infection. While the contributions of specific metabolic processes, such as iron acquisition \[[@ppat.1008010.ref024],[@ppat.1008010.ref025],[@ppat.1008010.ref035],[@ppat.1008010.ref036],[@ppat.1008010.ref054]--[@ppat.1008010.ref057]\], nitrogen utilization through urease activity \[[@ppat.1008010.ref058]\], allantoin metabolism \[[@ppat.1008010.ref059]\], and psicose metabolism \[[@ppat.1008010.ref060]\] in Kp pathogenesis have been explored, this study reveals a role for central metabolism and metabolic flexibility during Kp infection.

GltA is a type II citrate synthase, which are characteristically found in Gram-negative bacteria. The Kp GltA, which is ubiquitous in the species, is closely related to the citrate synthases of other members of *Enterobacteriaceae*, such as *Salmonella enterica* and *E*. *coli*, sharing 96% and 95% amino acid sequence identity, respectively. Interestingly, the Kp genome has two genes annotated as *gltA*. Apart from VK055_1802, VK055_2057 is also annotated as *gltA* (hereafter *gltA2*). The *gltA2* gene is universally present in *Klebsiella spp*. but not in other *Enterobacteriaceae* genera. I-TASSER 3D structure prediction \[[@ppat.1008010.ref061]--[@ppat.1008010.ref063]\] indicates that GltA2 is structurally similar to GltA despite sharing only 60% and 58% amino acid sequence identity with KPPR1 GltA and *E*. *coli* str. K-12 substr. MG1655 GltA, respectively. Our data demonstrate that GltA and GltA2 are functionally distinct, as the KPPR1Δ*gltA* mutant has a significant defect despite the presence of *gltA2*.

Our data indicate that the loss of *gltA* abrogates the *de novo* synthesis of glutamate and other key carbon skeletons for biosynthesis of amino acids, which is essential to bacterial growth. Glutamate is the fulcrum of glutamine, proline, arginine, and histidine metabolism \[[@ppat.1008010.ref064]\] ([S4 Fig](#ppat.1008010.s004){ref-type="supplementary-material"}). Glutamate is also needed for ammonia assimilation. In fact, glutamate and glutamine provide nitrogen for all nitrogen-containing components of the bacterial cell, and approximately 88% comes from glutamate \[[@ppat.1008010.ref065]\]. Studies in *E*. *coli* have shown that glutamate is the most abundant intracellular metabolite, with an absolute intracellular concentration of 96 mM \[[@ppat.1008010.ref066]\]. Additionally, after conversion to its D-enantiomer, glutamate serves as a component of bacterial peptidoglycan, which forms the cell wall and determines the rate of cell elongation \[[@ppat.1008010.ref067]\]. Thus, Kp lacking *de novo* synthesis of glutamate are incapable of proliferating unless glutamate can be acquired exogenously. This is highlighted by the fact that growth of KPPR1Δ*gltA* in minimal medium is rescued by the addition of glutamate in a dose-dependent manner ([S4 Fig](#ppat.1008010.s004){ref-type="supplementary-material"}). Alternatively, exogenous glutamine, proline, arginine, and histidine can facilitate growth through the central nitrogen metabolic circuit or through production of glutamate through degradation \[[@ppat.1008010.ref064]\]; however, supplementation of α-ketoglutarate at a high concentration was not sufficient for a complete restoration of growth, suggesting a lack of transporting mechanism ([Fig 3E and 3F](#ppat.1008010.g003){ref-type="fig"}). Additionally, our data demonstrate that dipeptides containing glutamate, glutamine, and histidine can support growth of GltA-deficient Kp ([Fig 2C](#ppat.1008010.g002){ref-type="fig"}, [S2 Data](#ppat.1008010.s011){ref-type="supplementary-material"}), indicating that Kp could scavenge dipeptides or polypeptides in the course of colonization and infection. Given that the total amino acid and protein concentration was higher in the *Lcn2*^*-/-*^ lung than the *Lcn2*^*+/+*^ lung ([Table 2](#ppat.1008010.t002){ref-type="table"}, [Fig 4C](#ppat.1008010.g004){ref-type="fig"}, [S3 Data](#ppat.1008010.s012){ref-type="supplementary-material"}) it is difficult to identify a single amino acid or polypeptide that rescues the loss of GltA. Rather, it is likely that a combination of free and/or peptide-bound amino acids permits metabolism-dependent niche invasion. Taken together, our findings suggest that stratifying *in vivo* environments as either nutritionally replete or deplete relative to the bacteria is appropriate, and that a systems biology approach of studying bacterial metabolic flexibility is beneficial for understanding the lifestyle of pathogenic bacteria.

By maintaining high metabolic flexibility, pathogenic bacteria can invade multiple niches, and thus, increase their chances of evolutionary success. For example, commensal *E*. *coli* living in the human gut favor glycolytic pathways that take advantage of the sugar-rich mucus lining \[[@ppat.1008010.ref051],[@ppat.1008010.ref052]\], whereas uropathogenic *E*. *coli* (UPEC) favor citric acid cycle-dependent pathways that take advantage of the nitrogen-rich urinary tract environment \[[@ppat.1008010.ref068]\]. As predicted, deletions in the glycolysis, pentose phosphate, and the Entner-Doudoroff pathways have little effect on fitness of *E*. *coli* in the urinary tract environment, whereas specific citric acid cycle components are necessary \[[@ppat.1008010.ref009],[@ppat.1008010.ref069]\]. Similarly, our previous InSeq study indicated the importance of the citric acid cycle during lung infection, identifying *gltA*, *frdA*, and *frdC* as fitness factors during lung infection \[[@ppat.1008010.ref026]\]. Only one glycolytic enzyme (*pfkB*), no pentose phosphate pathway enzymes, and no Entner-Doudoroff pathway enzymes were identified as fitness factors in the previous study \[[@ppat.1008010.ref026]\]. The data presented here support these findings, wherein increased amino acid levels in the *Lcn2*^*-/-*^ lung ameliorated the loss of *gltA*. Interestingly, the only other citric acid cycle enzyme enriched in the *Lcn2*^*-/-*^ lung was the fumarate reductase subunit, *frdD*; however, the other fumarate reductase subunits (*frdA-C*) did not display a similar phenotype ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}), and furthermore, these enzymes are only used during anaerobic growth in *E*. *coli* \[[@ppat.1008010.ref070]\]. Unlike *gltA*, transposon interruptions specific to glycolysis (*pfkB*, VK055_3061 \[*pgi*\], *tpiA*, *pyk*), the pentose phosphate pathway (*gnd*), and the Entner-Doudoroff pathway (VK055_1337 \[*tal1*\], VK055_2566 \[*tal3*\], *edd*) were not alleviated by the presence of increased glutamate family amino acids in the *Lcn2*^*-/-*^ lung ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}), highlighting the importance of *gltA* in conferring metabolic flexibility in this environment. Given that the necessity of *gltA* for complete fitness was seen in some but not all body sites ([Fig 6](#ppat.1008010.g006){ref-type="fig"}), and loss of *gltA* was alleviated through exogenous supplementation of amino acids ([Fig 4D](#ppat.1008010.g004){ref-type="fig"}, [S9 Fig](#ppat.1008010.s009){ref-type="supplementary-material"}), our data suggests that metabolic flexibility plays a similar role for Kp as it does for *E*. *coli*, where the ability to utilize available nutrients dictates site-specific fitness. Taken together, our findings indicate that the oxidative citric acid cycle is beneficial for Kp infection by permitting invasion of niches with different nutritional compositions; however, the role of the glycolysis, pentose phosphate pathway, and Entner-Doudoroff pathways during infection of other body sites remains to be explored.

Phenotypic metabolic flexibility has been used to delineate closely related species of the *K*. *pneumoniae* complex, which includes *K*. *pneumoniae*, *K*. *quasipneumoniae*, and *K*. *variicola*, as well as Kp pathogenic lineages. *K*. *quasipneumoniae* is an opportunistic pathogen that is frequently found as a colonizer \[[@ppat.1008010.ref071]\], whereas *K*. *variicola* causes more serious infections \[[@ppat.1008010.ref072]\]. The three members of this complex can be separated by their metabolic profile \[[@ppat.1008010.ref073]\]. Moreover, the Kp strain used in this study, KPPR1, has been shown to be more metabolically flexible than the less pathogenic Kp strain MGH 78578 \[[@ppat.1008010.ref074]\]. Finally, metabolism of D-arabinose \[[@ppat.1008010.ref073]\] and allantoin \[[@ppat.1008010.ref059]\] is associated with hypervirulent Kp strains and a variably-present psicose utilization locus is associated with human infection \[[@ppat.1008010.ref060]\]. As such, metabolic flexibility may be a critical dictator of the variation in clinical outcomes for different *Klebsiella spp*. or Kp pathogenic lineages, and *gltA* is likely a central hub for metabolizing diverse nutrients. Further exploration of the determinants of metabolic flexibility in Kp and the respective association with clinical outcomes is necessary to fully understand how specific metabolic capacity influences fitness during infection.

While this study significantly advances our understanding of the role that metabolic flexibility plays in determining fitness during infection, it is not without limits. Firstly, this study does not address the mechanism underlying the difference in amino acid and protein content between the *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ lung. In addition to antimicrobial activity, Lcn2 may have the ability to act as a growth and differentiation factor \[[@ppat.1008010.ref075],[@ppat.1008010.ref076]\] and modulate expression of lung epithelial cell genes \[[@ppat.1008010.ref025]\]. Therefore, deletion of *Lcn2* may impact lung homeostasis, leading to the increase in amino acid levels. Although understanding the mechanism underlying this phenotype is beyond the scope of this study, the phenotype served as a useful tool to observe the effect of increased glutamate family amino acid levels on Kp lung fitness. Secondly, this study exclusively uses the Kp strain KPPR1. Additional studies including different strains of the *K*. *pneumoniae* complex are necessary to fully understand the impact of metabolic flexibility during infection. Finally, we were unable to evaluate isocitrate dehydrogenase (*icd)* and the aconitate hydratase (*acnB*) as part of the role of oxidative citric acid cycle in metabolic flexibility during Kp infection. Unfortunately, *icd* and the aconitate hydratase *acnB* were not interrupted in our input pool of transposon mutants ([S1 Data](#ppat.1008010.s010){ref-type="supplementary-material"}). Additionally, the aconitate hydratases *acnA* and *acnB* are able to catalyze the same reaction \[[@ppat.1008010.ref077],[@ppat.1008010.ref078]\], and thus, a growth defect with a single *acnA* mutant may not be expected.

In summary, we have described a novel role for the Kp citrate synthase gene, *gltA*, as a critical mediator of site-specific fitness during infection due to its influence on metabolic flexibility. Taken together, our results represent an advancement in our understanding of Kp metabolism during infection and enhance our knowledge of how these serious infections manifest, such that we are better able to combat these dangerous bacteria.

Materials and methods {#sec004}
=====================

Ethics statement {#sec005}
----------------

This study was performed in strict accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals* \[[@ppat.1008010.ref079]\]. The University of Michigan Institutional Animal Care and Use Committee approved this research (PRO00007474).

Materials, media, and bacterial strains {#sec006}
---------------------------------------

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. *K*. *pneumoniae* KPPR1 \[[@ppat.1008010.ref027]\] and isogenic mutants were cultured in Luria-Bertani (LB, Becton, Dickinson and Company, Franklin Lakes, NJ) broth, or in M9 minimal medium (M9 salts \[Thermo Fisher Scientific, Waltham, MA\], 0.2 M MgSO~4~, 0.01 M CaCl~2~, with or without 0.4% glucose) at 37°C with shaking, or on LB agar at 30°C (Thermo Fisher Scientific). The KPPR1Δ*gltA* mutant was constructed as previously described \[[@ppat.1008010.ref026],[@ppat.1008010.ref031]\]. Briefly, electrocompetent KPPR1 cells containing a modified pKD46 plasmid encoding a spectinomycin resistance cassette \[[@ppat.1008010.ref026],[@ppat.1008010.ref031]\] were electroporated with a *gltA*-specific target site fragment containing a kanamycin resistance cassette isolated from the pKD4 plasmid \[[@ppat.1008010.ref031]\]. Transformants were selected at 37°C on LB agar containing 25 μg/ml kanamycin, re-cultured, and confirmed by colony PCR using flanking primers ([S1 Table](#ppat.1008010.s013){ref-type="supplementary-material"}). The *gltA* complementing plasmid pGltA was constructed using a Gibson Assembly Cloning Kit (New England Biolabs, Ipswich, MA). Briefly, the *gltA* sequence including its promoter was amplified from WT KPPR1 by PCR ([S1 Table](#ppat.1008010.s013){ref-type="supplementary-material"}) and ligated into the pACYC184 backbone \[[@ppat.1008010.ref080]\] to create the pGltA plasmid. The ligation mixture was transformed into NEB 10-beta Competent *E*. *coli* (New England Biolabs) by heat shock. Transformants were selected at 37°C on LB agar containing 30 μg/ml chloramphenicol, re-cultured, and confirmed by colony PCR using ([S1 Table](#ppat.1008010.s013){ref-type="supplementary-material"}). Singe transformants were then grown in batch culture for plasmid extraction using the Plasmid Midi Kit (Qiagen, Germantown, MD). KPPR1Δ*gltA* competent cells were prepared as previously described \[[@ppat.1008010.ref026]\], electroporated with the pGltA plasmid, and selected at 37°C on LB agar containing 30 μg/ml chloramphenicol. Following selection, transformants were re-cultured, and confirmed by colony PCR ([S1 Table](#ppat.1008010.s013){ref-type="supplementary-material"}) and by growth in M9 minimal medium.

Transposon library construction and InSeq {#sec007}
-----------------------------------------

Construction of the KPPR1 transposon library used in this study has been extensively described elsewhere \[[@ppat.1008010.ref026]\]. Insertion sequencing was performed as previously described \[[@ppat.1008010.ref026]\]. Following infection, total recovered transposon mutants were collected, gDNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD), and genomic sequences adjacent to insertion sites were amplified by PCR. Following amplification, Illumina sequencing adapters were ligated to amplified junction DNA fragments, and then fragments were sequenced on an Illumina HiSeq2500 Instrument (Illumina, San Diego, CA). Sequencing reads were filtered, mapped and normalized as described \[[@ppat.1008010.ref026]\].

Murine models of infection {#sec008}
--------------------------

Six- to 12-week-old C57BL/6J mice (*Lcn2*^*+/+*^, Jackson Laboratory, Jackson, ME) or isogenic *Lcn2*^*-/-*^ mice \[[@ppat.1008010.ref028]\] were used for all murine models of infection. Kp was cultured overnight in LB, then bacteria were pelleted, resuspended, and diluted in sterile phosphate-buffered saline (PBS) to the appropriate dose. For lung infection studies, a dose of 1×10^6^ CFU was used to provide sufficient representation of all mutants in the transposon library \[[@ppat.1008010.ref026]\]. Mice were anesthetized with isoflurane, inoculated in the pharynx, and the mouse was monitored until ambulatory. For validation of InSeq findings, 1×10^6^ CFU was inoculated in the pharynx either as single strains or as a 1:1 mix of the WT and mutant strain. After 24 hours, mice were euthanized by CO~2~ asphyxiation and lungs were collected, weighed, and homogenized in sterile PBS, and homogenates were dilution plated on selective media to determine bacterial load and competitive index. For bacteremia studies, inocula were prepared as above, and mice were inoculated intraperitoneally with approximately 5×10^5^ CFU. After 24 hours, mice were euthanized and bacterial load was assessed as above. For oral inoculation studies, inocula were prepared as above, and mice were inoculated orally with approximately 5×10^6^ CFU. After 48 hours, mice were euthanized and bacterial load was assessed as above. In all models, mice were monitored daily for signs of distress (hunched posture, ruffled fur, decreased mobility, and dehydration) and euthanized at predetermined timepoints. No blinding was performed between experimental groups.

Preparation of recombinant human lipocalin 2 protein and Lcn2 growth assay {#sec009}
--------------------------------------------------------------------------

Human lipocalin 2 was recombinantly expressed, purified, and validated as previously described \[[@ppat.1008010.ref055],[@ppat.1008010.ref081],[@ppat.1008010.ref082]\]. WT KPPR1 and various isogenic mutants were grown overnight in LB, then inoculated in RPMI with 10% (v/v) heat-inactivated human serum with or without 1.6 μM purified recombinant human Lcn2 at a concentration of 1 × 10^3^ CFU/mL. Cultures were incubated overnight at 37°C with 5% CO~2~, and bacterial density was enumerated by dilution plating.

BioLog Phenotype MicroArray analysis {#sec010}
------------------------------------

BioLog Phenotype MicroArrays (Biolog, Hayward, CA) analysis was performed in accordance with manufacturer's instructions with some modifications. WT KPPR1 and KPPR1Δ*gltA* were cultured overnight in LB, then bacteria were pelleted, washed once in sterile PBS, then re-suspended in sterile PBS. Each strain was diluted in IF-0 medium to a final OD~600~ of 0.035, then diluted again to final inoculation concentrations as per manufacturer's instruction. The final inoculum (100 μL) was plated onto plates PM1, PM2, and PM3. Sodium pyruvate (Thermo Fisher Scientific) was used as a carbon source for PM3 at a final concentration of 2 mM in accordance with previous metabolic phenotype analysis \[[@ppat.1008010.ref073]\]. After inoculation, plates were sealed to avoid cross contamination of volatile compounds produced during Kp growth \[[@ppat.1008010.ref073],[@ppat.1008010.ref083]\] and statically incubated overnight at 37°C. Following overnight incubation, growth was measured at OD~595~.

Growth curves {#sec011}
-------------

The WT KPPR1 and KPPR1Δ*gltA* strains were cultured overnight in LB broth, then diluted to a uniform OD~600~ of 0.01 in the culture medium of interest the following day. Amino acids were supplemented at 10 mM unless otherwise indicated, and carbon sources were supplemented at 5 mg/mL. Cultures were incubated at 37°C with aeration and OD~600~ readings were taken every 15 min using an Eon microplate reader with Gen5 software (Version 2.0, BioTek, Winooski, VT) for up to 24 hours. To simultaneously assess doubling time, growth rate, lag time, non-sigmoidal growth due to stress and bacterial density, area under the curve analysis was used to quantify differences in growth \[[@ppat.1008010.ref037],[@ppat.1008010.ref038]\] using Prism 6 (GraphPad Software, La Jolla, CA).

Serum growth assay {#sec012}
------------------

The WT KPPR1 and KPPR1Δ*gltA* strains were cultured overnight in LB broth with antibiotic supplementation, if necessary. Bacteria were then washed with M9 minimal media by centrifugation, resuspended, and diluted to an OD~600~ of 0.01 in M9 minimal media without glucose, supplemented with 20% (v/v) murine or 10% (v/v) human sera. For some experiments, sera were heat-inactivated at 56°C for 30 minutes. Cultures were grown at 37°C and OD~600~ was measured using an Eon microplate reader with Gen5 software (Version 2.0, BioTek, Winooski, VT) for up to 24 hours.

BALF and organ homogenate growth assay {#sec013}
--------------------------------------

Six- to 12-week-old C57BL/6J mice (*Lcn2*^*+/+*^, Jackson Laboratory, Jackson, ME) or isogenic *Lcn2*^*-/-*^ mice \[[@ppat.1008010.ref028]\] were used for BALF and organ collection. Briefly, mice were euthanized by CO~2~ asphyxiation and tracheas were exposed. A small incision was made in the trachea, and polyethylene tubing (external diameter 0.965 mm, internal diameter 0.58 mm, BD, Franklin Lakes, NJ) attached to a 23-gauge luer-stub adaptor and syringe containing 2 mL sterile PBS. Following tubing insertion, 4--0 silk suture (Ethicon, Somerville, NJ) was used to secure the trachea and then the lungs were flushed with PBS. Organs were collected following BALF collection. BALF was kept on ice until processing, wherein BALF was centrifuged at 21,130 x *g* for 30 min at 4°C to pellet contaminating bacteria, then supernatant was stored at -80°C. Rifampin was added to BALF to a final concentration of 30 μg/ml immediately prior to use. Organs were homogenized in 1.5 mL sterile PBS, then sterile filtered through a 0.22 μM PVDF filter (MilliporeSigma, Burlington, MA). The WT KPPR1 and KPPR1Δ*gltA* strains were cultured overnight in LB broth with antibiotic supplementation, if necessary. Bacteria were washed with PBS by centrifugation, resuspended, diluted to an OD~600~ of 0.1 in sterile PBS or sterile PBS with amino acid supplement, then mixed with BALF or organ homogenate from independent mice at a ratio of 1:9 inoculum: BALF/homogenate. Cultures were incubated at 37°C with aeration and OD~600~ was measured using an Eon microplate reader with Gen5 software (Version 2.0, BioTek, Winooski, VT) for up to 24 hours.

Metabolomic analysis of BALF {#sec014}
----------------------------

For metabolomic analysis 100 μL of BALF was used. Following lipid extraction, BALF protein content was measured by BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) following manufacturer's instruction. 20 μL was set aside to create a pooled sample from all study samples, and the remaining 80 μL of each BALF sample was prepared for GC-MS analysis according to manufacturer instructions using the Phenomenex EZFaast Free Amino Acids Analysis GC-MS kit (Phenomenex, Torrance, CA, USA). Briefly, BALF samples were combined with an internal standard (norvaline) and subjected to cation exchange solid phase extraction to purify amino acids from proteins, salts and other matrix components. The amino acids were then derivatized using a proprietary reagent and catalyst, the solvent was evaporated under a gentle nitrogen stream at room temperature, and finally the sample was resuspended for GC analysis. Quality control samples were prepared by pooling equal volumes of each sample and were injected at the beginning and the end of each analysis and after every 10 sample injections to provide a measurement of the system's stability and performance as well as reproducibility of the sample preparation method. The pooled sample was treated identically to the study samples and was analyzed along with the samples for quality control purposes. Calibration standards were prepared containing all 20 proteinogenic amino acids at concentrations of 10, 25, 50 and 100 μM and were analyzed in replicate along with samples to enable absolute quantitation of amino acids.

GC-MS analysis was performed on an Agilent 69890N GC -5975 MS detector with the following parameters: a 1 μL sample was injected with a 1:15 split ratio on a ZB-AAA 10 m column (Phenomenex, Torrance, CA, USA) with a He gas flow rate of 1.1 mL/min. The GC oven initial temperature was 110°C and was increased at 30°C per minute to 320°C. The inlet temperature was 250°C and the MS-source and quad temperatures were 230° and 150°C respectively. GC-MS data were processed using MassHunter Quantitative Analysis software version B.07.00. Amino acids were quantitated as μM/L BALF using linear calibration curves generated from the standards listed above. To generate these curves, all peak areas in samples and calibration standards were first normalized to the peak area of the internal standard, norvaline. Based on replicate analysis of biological samples, the quantitative variability for all reported amino acids using this method is \<15% RSD.

Statistical analysis {#sec015}
--------------------

All *in vitro* experimental replicates represent biological replicates. For *in vitro* studies, except metabolomic analysis, two-tailed Student's *t*-tests or ANOVA followed by Tukey's multiple comparisons post-hoc test was used to determine significant differences between groups. For metabolomic analysis, R version 3.5 and the "gplots," "pca3d," and "rgl" packages were used for data visualization and differences were assessed by two-sample Wilcoxon test and controlled for false discovery rate using the two-stage linear step-up procedure of Benjamini and Hochberg (2006) with Q = 5%. All animal studies except the InSeq study were replicated at least twice. Competitive indices were log transformed and a one-sample *t-*test was used to determine significant differences from a hypothetical value of 0 or two-tailed Student's *t-*test was used to determine significant differences between groups. All CFU values were log~10~ transformed for analysis. A *P* value of less than 0.05 was considered statistically significant for the above experiments, and analysis was performed using Prism 6 (GraphPad Software, La Jolla, CA). For InSeq analysis, a *P* value was first calculated for each insertion using an exact Poisson test for comparing the two groups, and then the insertion-level *P* values were combined using Fisher\'s method \[[@ppat.1008010.ref084]\] to obtain the statistical significance for each gene. Finally, the *P* values were adjusted to control the false discovery rate (Dabney A and Storey JD. qvalue: Q-value estimation for false discovery rate control. R package version 1.43.0.). A *P* value of less than 1.3×10^−5^ was considered statistically significant. This led to a list of 1,678 enriched genes, which was then shortened to 49 genes by limiting analysis to genes with a log *Lcn2*^*+/+*^: *Lcn2*^*-/-*^ insertion ratio greater or less than 3 standard deviations from the mean log *Lcn2*^*+/+*^: *Lcn2*^*-/-*^ insertion ratio. 43 of these 49 genes had an FDR adjusted *P* value less than 1.3×10^−5^.

Supporting information {#sec016}
======================

###### Summary of comparative InSeq study.

\(A\) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were retropharyngeally inoculated with approximately 1×10^6^ CFU of a pool of \~25,000 transposon mutants to compare mutant frequencies in *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice during lung infection. Twenty-four hours post-inoculation, total lung CFU were collected for DNA extraction, Illumina sequencing of transposon junctions was performed, reads were mapped to the KPPR1 reference genome, and insertion read counts were compared between *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice. (B) The log~10~ insertion count ratio was calculated for each gene. A ratio of 0 indicated that there is no difference in insertion read counts between *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice, thus indicating that the KPPR1 gene does not have any interaction with Lcn2. Genes with log~10~ insertion read count ratios greater than or less than 3 standard deviations from the mean (mean ± S.D. = 0.094 ± 0.53) suggest a strong interaction between that gene and Lcn2. 49 genes meet this criterion. (C) Volcano plot summarizing the calculated *P* values of each log~10~ insertion read count difference counts between *Lcn2*^*+/+*^ and *Lcn2*^*-/-*^ mice. The dotted line (significant *P* value cutoff = 1.3×10^−5^) indicates the threshold for consideration of a *P* value as significant after correction for multiple comparisons. 43 of 49 genes with log~10~ insertion read count ratios greater than or less than 3 standard deviations from the mean have a *P* value \< 1.3×10^−5^, including *gltA*, which is shown in black. (D) Locations and frequencies of transposon insertions in *gltA*. (E) WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA were grown in LB (n = 3, mean displayed ± SEM). (F) Area under curve analysis of WT KPPR1, KPPR1Δ*gltA*, and KPPR1Δ*gltA*pGltA growth in LB (n = 3, Tukey's multiple comparison test following ANOVA, mean displayed ± SEM).

(TIF)

###### 

Click here for additional data file.

###### Summary of bacterial burden during lung infection.

\(A\) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were retropharyngeally inoculated with approximately 1×10^6^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA* and lung bacterial burden was measured after 24 hours (n = 10 per group, mean displayed, \**P* \< 0.05, \*\*\**P* \< 0.0005, Student's *t* test). (B) C57BL/6J mice were retropharyngeally inoculated with approximately 1×10^6^ CFU of either WT KPPR1 or KPPR1Δ*gltA* and lung bacterial burden was measured after 24 hours (n = 10 per group, mean displayed, \**P* \< 0.05, Student's *t* test).

(TIF)

###### 

Click here for additional data file.

###### Loss of *gltA* is not complemented by citrate the in the presence of a glycolytic substrate, but is complemented by citrate and glutamate when provided as a gluconeogenic substrate.

WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media with (A) 10 mM citrate, (B) 0.4% glucose, or (C) 0.4% glucose and 10 mM citrate (n = 3, mean displayed ± SEM). (D) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* grown in M9 minimal media with 10 mM citrate, 0.4% glucose, or 0.4% glucose and 10 mM citrate (n = 3, \*\*\**P* \< 0.0005, \*\*\*\**P* \< 0.00005, Student's *t* test, mean displayed ± SEM).

(TIF)

###### 

Click here for additional data file.

###### Summary of the roles of glutamate family amino acids.

Glutamate family amino acids enter the citric acid cycle via α-ketoglutarate and exit the citric acid cycle for protein and peptidoglycan biosynthesis or nitrogen assimilation after conversion to glutamate. Glutamate plays a central role in these processes due to its position as a hub of multiple metabolic pathways. Deletion of *gltA* inhibits the ability of Kp to use metabolic substrates outside of the glutamate family of amino acids, resulting in significantly less metabolic flexibility.

(TIF)

###### 

Click here for additional data file.

###### GltA is necessary for glycolytic substrate utilization.

WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 5 mg/mL of (A) acetate, (B) arabinose, (C) fucose, (D) galactose, (E), gluconate, (F) glucose, (G) lactose, (H) pyruvate, (I) raffinose, (J) rhamnose, or (K) xylose (n = 3, mean displayed ± SEM). (L) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* growth in M9 minimal media + 5 mg/mL specific sugar (n = 3, \*\**P* \< 0.005, \*\*\**P* \< 0.005, Student's t-test, mean displayed ± SEM).

(TIF)

###### 

Click here for additional data file.

###### Auxotrophy due to deletion of *gltA* is rescued by glutamate in a dose-dependent manner.

\(A\) WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 0.4% glucose with increasing concentrations of glutamate (n = 3, mean displayed ± SEM). (B) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 0.4% glucose with increasing concentrations of glutamate (n = 3, \*\*\*\**P* \< 0.00005, Tukey's multiple comparison test following ANOVA, mean displayed ± SEM).

(TIF)

###### 

Click here for additional data file.

###### *gltA* growth in non-heat-inactivated murine serum.

\(A\) WT KPPR1 and KPPR1Δ*gltA* were grown in M9 minimal media + 20% non-heat-inactivated murine serum (n = 3, mean displayed ± SEM). (B) AUC analysis of WT KPPR1 and KPPR1Δ*gltA* growth in M9 minimal media + 20% non-heat-inactivated murine serum (n = 3, \*\**P* \< 0.005, Student's t-test, mean displayed ± SEM).

(TIF)

###### 

Click here for additional data file.

###### Summary of bacterial burden during bacteremia and oral infection.

\(A\) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were intraperitoneally inoculated with approximately 1×10^6^ CFU of a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA* and bacterial burden was measured after 24 hours (n = 9--11 per group, mean displayed, \**P* \< 0.05, Student's *t* test). (B) C57BL/6J mice or isogenic *Lcn2*^*-/-*^ mice were orally inoculated with approximately 5×10^6^ CFU of a 1:1 mix of WT KPPR1 or KPPR1Δ*gltA* and cecal bacterial burden was measured after 48 hours (n = 8--9 per group, mean displayed, Mann-Whitney test). (C) C57BL/6J mice were orally inoculated with approximately 1×10^6^ CFU of WT KPPR1 or KPPR1Δ*gltA* and cecal bacterial burden was measured after 48 hours (n = 9--10 per group, mean displayed, Mann-Whitney test).

(TIF)

###### 

Click here for additional data file.

###### Loss of GltA is rescued by glutamate family amino acids in *Lcn2^+/+^* organ homogenates.

Murine (A) spleen, (B) liver, and (C) cecum homogenate generated from uninfected C57BL/6J mice with or without amino acids was inoculated with a 1:1 mix of WT KPPR1 and KPPR1Δ*gltA* or WT KPPR1 and KPPR1Δ*gltA*pGltA. Bacterial burden was measured after 24 hours, and log~10~ competitive index of the mutant strain compared to the WT strain was calculated for each sample (n = 4 mice per group, \**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005, \*\*\*\**P* \< 0.00005, one-sample *t* test or Tukey's multiple comparison test following ANOVA).

(TIF)

###### 

Click here for additional data file.

###### Summary of comparative InSeq data.

(XLSX)

###### 

Click here for additional data file.

###### Summary of BioLog Phenotype MicroArray data.

(XLSX)

###### 

Click here for additional data file.

###### Summary of individual amino acid and protein concentrations from *Lcn2^+/+^* and *Lcn2^-/-^* BALF.

(XLSX)

###### 

Click here for additional data file.

###### Primers used in this study.

(XLSX)

###### 

Click here for additional data file.
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